Stephens Inc. AR Has $4.11 Million Holdings in Endologix, Inc. (ELGX)
Stephens Inc. AR boosted its holdings in Endologix, Inc. (NASDAQ:ELGX) by 10.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 845,016 shares of the medical instruments supplier’s stock after buying an additional 80,328 shares during the period. Stephens Inc. AR owned 1.01% of Endologix worth $4,107,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Quantbot Technologies LP purchased a new stake in Endologix in the 1st quarter worth $160,000. MARSHALL WACE ASIA Ltd purchased a new stake in Endologix in the 1st quarter worth $323,000. Marshall Wace North America L.P. purchased a new stake in Endologix in the 1st quarter worth $323,000. American International Group Inc. increased its stake in Endologix by 7.1% in the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 3,290 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC increased its stake in Endologix by 19.0% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 50,000 shares of the medical instruments supplier’s stock worth $362,000 after buying an additional 8,000 shares in the last quarter.
A number of brokerages have issued reports on ELGX. Oppenheimer Holdings, Inc. lowered Endologix from an “outperform” rating to a “market perform” rating and set a $6.00 price target for the company. in a research note on Thursday, May 18th. ValuEngine lowered Endologix from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research upgraded Endologix from a “hold” rating to a “strong-buy” rating and set a $5.75 price objective for the company in a research report on Monday, July 24th. Canaccord Genuity restated a “hold” rating and set a $5.00 price objective on shares of Endologix in a research report on Thursday, May 18th. Finally, BTIG Research lowered Endologix from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a research report on Thursday, May 18th. Two analysts have rated the stock with a sell rating and eleven have given a hold rating to the company’s stock. Endologix currently has a consensus rating of “Hold” and an average target price of $6.28.
COPYRIGHT VIOLATION NOTICE: “Stephens Inc. AR Has $4.11 Million Holdings in Endologix, Inc. (ELGX)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/12/stephens-inc-ar-has-4-11-million-holdings-in-endologix-inc-elgx.html.
Shares of Endologix, Inc. (ELGX) traded down 2.42% on Tuesday, hitting $4.43. 86,426 shares of the company were exchanged. Endologix, Inc. has a 52-week low of $4.08 and a 52-week high of $13.30. The stock’s market capitalization is $369.61 million. The firm’s 50-day moving average is $4.47 and its 200-day moving average is $5.61.
Endologix (NASDAQ:ELGX) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. The business had revenue of $48.60 million during the quarter, compared to analysts’ expectations of $47.58 million. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The company’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.20) earnings per share. Equities research analysts predict that Endologix, Inc. will post ($0.62) earnings per share for the current year.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Stock Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related stocks with our FREE daily email newsletter.